BTS BIOPHARMA Trademark

Trademark Overview

On Friday, June 19, 2020, a trademark application was filed for BTS BIOPHARMA with the United States Patent and Trademark Office. The USPTO has given the BTS BIOPHARMA trademark a serial number of 90011011. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 12, 2024. This trademark is owned by BTS Biopharma Inc.. The BTS BIOPHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research in the field of pharmaceuticals for treatment of autoimmune diseases; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific study and research in the field(s) of medicine, namely, for the prevention and treatment of cancer, tumor, autoimmune diseases, diabetes, cardiovascular diseases, ophthalmic diseases, infectious diseases, and respiratory diseases
bts biopharma

General Information

Serial Number90011011
Word MarkBTS BIOPHARMA
Filing DateFriday, June 19, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 17, 2020

Trademark Statements

NOT AVAILABLE"BIOPHARMA"
Goods and ServicesResearch in the field of pharmaceuticals for treatment of autoimmune diseases; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific study and research in the field(s) of medicine, namely, for the prevention and treatment of cancer, tumor, autoimmune diseases, diabetes, cardiovascular diseases, ophthalmic diseases, infectious diseases, and respiratory diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 16, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBTS Biopharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressReno, NV 89521
Party NameBTS Biopharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressElkridge, MD 21075

Trademark Events

Event DateEvent Description
Tuesday, June 23, 2020NEW APPLICATION ENTERED
Thursday, July 16, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 22, 2020ASSIGNED TO EXAMINER
Wednesday, September 23, 2020EXAMINERS AMENDMENT -WRITTEN
Wednesday, September 23, 2020EXAMINERS AMENDMENT E-MAILED
Wednesday, September 23, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, September 23, 2020EXAMINER'S AMENDMENT ENTERED
Monday, October 5, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 28, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 17, 2020PUBLISHED FOR OPPOSITION
Tuesday, November 17, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 25, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Wednesday, May 19, 2021OPPOSITION INSTITUTED NO. 999999
Friday, May 27, 2022OPPOSITION TERMINATED NO. 999999
Friday, May 27, 2022OPPOSITION DISMISSED NO. 999999
Friday, May 27, 2022TTAB RELEASE CASE TO TRADEMARKS
Tuesday, July 12, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 1, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, August 1, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 1, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, January 10, 2023SOU EXTENSION 1 GRANTED
Tuesday, January 10, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, January 10, 2023SOU EXTENSION 1 FILED
Thursday, January 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 11, 2023SOU EXTENSION 2 FILED
Tuesday, July 18, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 18, 2023SOU EXTENSION 2 GRANTED
Wednesday, July 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 9, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 9, 2024SOU EXTENSION 3 FILED
Thursday, January 11, 2024ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST
Monday, January 29, 2024RESPONSE TO ITU OFFICE ACTION ENTERED
Monday, January 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 13, 2024SOU EXTENSION 3 GRANTED
Wednesday, February 14, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 12, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, August 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

biopharma diseases research treatment autoimmune field cancer prevention namely tumor ophthalmic